Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
View:
• Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2
• \-
Locations
Other Locations
Guinea
CHU Donka 030 BP 554
RECRUITING
Conakry
Senegal
Hôpital Aristide Le Dantec, Avenue Pasteur,
RECRUITING
Dakar
Contact Information
Primary
Ndella Ms DIOUF, MD
ndella.diouf@gfaop.org
00(221)77 656 49 13.
Backup
BRENDA Ms MALLON, MSc
brenda.mallon@gustaveroussy.fr
0033142115411
Time Frame
Start Date: 2021-11-15
Estimated Completion Date: 2030-09-01
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: French Africa Pediatric Oncology Group
Collaborators: Gustave Roussy, Cancer Campus, Grand Paris